Urolog. pro Praxi, 2010; 11(2): 82-85
Molecular genetics and prostate cancer gene (PCA3) in diagnosing prostate cancer
- Urologické oddělení, Ústřední vojenská nemocnice, Praha
Current dignosis of prostate cancer is based on digital rectal examination or testing of prostate specific antigen level in serum. Both
methods have several shortcomings even if used in combination. Low sensitivity often leads to negative findings in prostate biopsy and
need to repeat it. The only possibility how to overcome this unfavourable situation is to discover different methods of prostate cancer
detection. One of the more recently used method is the detection of ribonucleic acid specifically expressed in cancer cells called prostate
cancer gene 3 (PCA3). Based on available informations this method allows to predict positive biopsy result and also agressiveness of the
diagnosed cancer. Article summarized contemporary knowledge on this issue from description of the gene and method of detection to
potential utilization in everyday practice.
Keywords: prostate cancer, PCA3, PSA, biopsy
Published: May 1, 2010 Show citation
References
- Jansen FH, Roobol M, Bangma CH, van Schaik RH. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem 2008; 54(12): 1999-2006.
Go to original source... 
Go to PubMed... - Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59(23): 5975-5979. Go to PubMed...
- Popa I, Fradet Y, Beaudry G, et al. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 2007; 20: 1121-1127. Go to original source... Go to PubMed...
- de la Taille A. Progensa PCA3 test for prostate cancer detection. Expert Rev Mol Diagn 2007; 7(5): 491-497. Go to original source... Go to PubMed...
- Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3 (PCA3)), a highly prostate cancer-specific gene. Urology 2003; 62(5, Suppl 1): 34-43. Go to original source... Go to PubMed...
- Meng FJ, Shan A, Jin L, Young CY. The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol Biomarkers Prev 2002; 11(3): 305-309.
- de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62(9): 2695-2698.
- van Gils MP, Cornel EB, Hessels D, et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 2007; 67(8): 881-887. Go to original source... Go to PubMed...
- Groskopf J, Aubin SMJ, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-1095. Go to original source... Go to PubMed...
- Klečka J, Hora M, Pešta M, Holubec L, Topolčan O, Eret V. DD3 (Differential Display Code 3) - nový marker v diagnostice karcinomu prostaty. Výroční konference České urologické společnosti ČLS JEP, Plzeň, 10.-12.10.2007 (abstrakt). Čes Urol 2007; 11: 20. Go to original source...
- Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44(1): 8-15. Go to original source... Go to PubMed...
- Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69(3): 532-535. Go to original source... Go to PubMed...
- Kirby RS, Fitzpatrick JM, Irani J. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int 2009; 103(4): 441-445. Go to original source... Go to PubMed...
- Sokoll L, Ellis W, Lange P, et al. A multicenter evaluation of the PCA3 molecular urine test: preanalytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 2008; 389: 1-6. Go to original source... Go to PubMed...
- Haese A, de la Taille A, van Poppel H, et al. Clinical utility of PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-1088. Go to original source... Go to PubMed...
- Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004; 101: 2001-2005. Go to original source... Go to PubMed...
- Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179(4): 1587-1592. Go to original source... Go to PubMed...
- Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179(5): 1804-1809. Go to original source... Go to PubMed...
- van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008; 68(11): 1215-1222. Go to original source... Go to PubMed...
- Verhaegh GW, van Bokhoven A, Smit F, Schalken JA, Bussemakers MJ. Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 2000; 275(48): 37496-37503. Go to original source... Go to PubMed...
- Vik V, Šácha P, Koukolík F, Konvalinka J, et al. Co nového víme o PSMA (prostatický specifický membránový antigen): z pohledu urologa. Urol listy 2007; 5(4): 10-13.
- Leman ES, Cannon GW, Trock BJ, et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 2007; 69(4): 714-720. Go to original source... Go to PubMed...